Elements for a Public Summary
|
|
- Britney Foster
- 5 years ago
- Views:
Transcription
1 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis Osteoarthritis is the most common type of joint disease. It represents a group of conditions that result in changes that can be seen microsopically and by X-Ray. It can be thought of as a worsening condition arising from biochemical breakdown of joint cartilage (protective padding between bones) in the joint cavity. However, the current view is that osteoarthritis involves not only the joint cartilage but also the entire joint, including the bone under the cartilage (subchondral bone) and joint cavity. Osteoarthritis usually involves the weight-bearing joints, including the knees, hips, upper and lower part of the spine, and feet. Other commonly affected joints include the joints of the fingers and wrist. Historically, osteoarthritis has been divided into primary and secondary forms. Secondary osteoarthritis is easier to understand: It refers to disease of flexible (synovial) joints that results from something that has damaged the joint tissues (eg, trauma to joint cartilage or subchondral bone). Secondary osteoarthritis can occur in relatively young individuals. The progression of osteoarthritis is slow, occurring over several years or decades. Over this period, the patient can become less and less active and thus more likely to have problems related to decreasing physical activity (including weight gain). Early in the disease, the joints may appear normal. However, the patient s walking may change in an attempt to avoid pain, if weight-bearing joints are involved. Pain is usually the initial source of problems in osteoarthritis, with the disease s main symptom being deep, achy joint pain worsened by a lot of use. Also, reduced range of motion and grinding sounds (crepitus) are frequently present. Stiffness during rest (gelling) may develop, with morning joint stiffness usually lasting for less than 30 minutes. To begin with, pain can be relieved by rest and may respond to simple pain killers. However, joints may become unstable as the osteoarthritis progresses; therefore, the pain may become worse (even during rest) and may not respond to medications. 1 Rheumatoid arthritis Rheumatoid arthritis (RA) is a long-term inflammatory disease of unknown cause. It is thought that the disease may start after an external trigger (eg, cigarette smoking, infection, or trauma) that causes an autoimmune reaction, leading to changes of the joint cavity such as swelling, new fibrous tissue formation and the fusion of affected joints, along with the potential for manifestations outside of the joints. The common feature of rheumatoid arthritis (RA) is long-term arthritis that affects multiple joints of the hands and feet, although any joint lined by a synovial membrane (a connective tissue that lines the joint and produces lubricating fluid) may be involved. The severity of RA may change over time, but long-term RA most commonly results in some joint destruction, deformity, and a significant decline in ability to use. Involvement of organs such as the skin, heart, lungs, and eyes can also be significant. Patients with RA may report difficulty performing activities of daily living (ADLs), such as dressing, standing, walking, personal hygiene, or use of hands. In addition to articular deterioration, other symptoms (eg, fatigue, feeling generally unwell, morning stiffness, weight loss, and mild fever) may be present. In most patients, RA starts slowly. It may begin with symptoms such as fever, feeling generally unwell, joint pain, and weakness, before the appearance of obvious joint inflammation and swelling. A small percentage (about 10%) of patients with this disease has a quick onset with the development of inflammation of the synovial membrane (synovitis) and symptoms not involving the joints. Improvement is uncommon, especially after the first 3-6 months. 2 Ankylosing spondylitis. PhV Page 90/123
2 Ankylosing spondylitis (AS) is a long-term disorder mainly involving the joints of the hip and spine, although it can also cause other problems such as arthritis, swelling where a tendon or ligament attaches to the bone (enthesitis), and symptoms not involving the joints. The cause of AS is not understood completely; however, a strong genetic link exists. Early diagnosis of AS is important because early medical and physical therapy may improve the outcome. Patient education is important so that the patient knows about the symptoms, course, and treatment of the disease. Treatment measures include medication, physical therapy, and surgical. Symptoms of AS include those related to inflammatory back pain, enthesitis and arthritis, and other symptoms not involving the joints. Chronic pain and stiffness are the most common complaints of patients with AS. More than 70% of patients report daily pain and stiffness. Fatigue is another common complaint, occurring in about 65% of AS patients. Most patients report their fatigue to be moderately severe. Increased levels of fatigue are associated with increased pain and stiffness and decreased ability to function. Fever and weight loss may occur during periods of active disease. 3 VI.2.2 Summary of treatment benefits Osteoarthritis The goals of osteoarthritis treatment include pain relief and improvement of functional status. Ideally, patients should receive a combination of treatment with medication and other treatments. For knee osteoarthritis, the ACR (The American College of Rheumatology) recommends using one of the following: Paracetamol Oral non-steroidal anti-inflammatory drugs (NSAIDs) Topical non-steroidal anti-inflammatory drugs (NSAIDs) Tramadol Corticosteroid injections into the joints The choice of pain relief medication for an individual patient should take into account the trade-off between benefits and adverse effects, which differs across analgesics. Patient age, other disease conditions, and other medication also being taken are key considerations. The goals of medication in osteoarthritis are to ease symptoms and to prevent complications. Medicines injected into the joints include corticosteroid or sodium hyaluronate (ie, hyaluronic acid [HA] or hyaluronan), which may provide pain relief and have an anti-inflammatory effect on the affected joint. Begin treatment with paracetamol for mild or moderate osteoarthritic pain without inflammation. If the response to paracetamol is not satisfactory or if the osteoarthritis is inflammatory, consider using an NSAID. Use the lowest effective dose or intermittent dosing if symptoms are intermittent, then try full doses if the patient s response is not enough. Options in patients at a higher risk of gastrointestinal side-effects from NSAIDs include the addition of other medications (e.g. a proton-pump inhibitor or misoprostol) and the use of the particular NSAIDs (e.g. selective cyclooxygenase (COX)-2 inhibitor celecoxib instead of a nonselective NSAID). Lifestyle changes, particularly exercise and weight loss, are very important in the management of osteoarthritis. Rheumatoid arthritis The best care of patients with rheumatoid arthritis (RA) is achieved by including both medication-based and non-medication-based treatments. Many non-medication-based treatments are available for this disease, including exercise, diet, massage, counseling, stress reduction, physical therapy, and surgery. PhV Page 91/123
3 Medication-based treatments comprise of several types of medicine, including non-steroidal anti-inflammatory drugs (NSAIDs), non-biologic and biologic disease-modifying antirheumatic drugs (DMARDs), immunosuppressants, and corticosteroids. Early therapy with DMARDs has become the standard of care, in that it is capable not only of slowing disease progression better than later treatment but also, potentially, of inducing more remissions. NSAIDs reduce swelling and pain. However, they do not slow joint destruction and so are not sufficient to treat RA when used alone. Like corticosteroids, NSAIDs can be reduced in dose or discontinued with successful DMARD therapy. There are various surgical treatments for RA. Commonly used NSAIDs include ibuprofen, naproxen, ketoprofen, celecoxib, and diclofenac. is approved for the relief of signs and symptoms of RA. It may have fewer gastrointestinal side effects than some other NSAIDs. Administer the lowest possible dose for each patient. Use of celecoxib has been associated with an increased risk of heart-related side effects. Ankylosing spondylitis There is no definite disease-modifying treatment available for people with ankylosing spondylitis (AS). Early diagnosis is important. Patient education is vital to familiarize the patient with the symptoms, course, and treatment of the disease. Treatment measures include medication, surgical, and physical therapy. No drugs have been proved to modify the course of the disease, although tumor necrosis factor alpha (TNF-α) blockers appear to have potential. Hospital care is generally not necessary for patients with AS, apart from those with other diseases and those requiring surgery. Non-steroidal anti-inflammatory drugs (NSAIDs) improve the symptoms of the disease by reducing pain and decreasing inflammation. Numerous choices are available, and they are separated into different groups. If one NSAID is ineffective, another from a different group can often provide relief. Efficacy and side effects differ among NSAIDs. VI.2.3 Unknowns relating to treatment benefits Based on the currently available data, no gaps in knowledge about the effectiveness of the drug in the target population were identified, that would warrant further effectiveness studies. Furthermore, there is no evidence to suggest that treatment results would be different in any subgroup of the target population, for any of the indications, taking into account factors such as age, sex and race or organ impairment. VI.2.4 Summary of safety concerns Important identified risks Gastrointestinal bleeding and Gastrointestinal ulceration Upper gastrointestinal complications [perforations, ulcers or bleedings], some of them causing death, have occurred in patients taking Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or aspirin at the same time, or patients with a history of gastrointestinal disease, Yes, by informing patients with stomach ulceration or gastrointestinal bleeding to avoid Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs. PhV Page 92/123
4 Cardiovascular events, including heart attacks (myocardial infarctions) and strokes (cerebral apoplexy) Kidney side effects (renal toxicity) fluid retention and swelling (oedema) High blood pressure (hypertension) Allergic reactions (hypersensitivity reactions) Liver damage (hepatotoxicity) such as ulceration and gastrointestinal bleeding. There is further increase in the risk of gastrointestinal side effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken at the same time as aspirin (even at low doses). A study has shown an increased number of serious cardiovascular events, mainly heart attack, in people taking Fluid retention and swelling have been observed in patients taking As with all NSAIDS, celecoxib can cause high blood pressure or make existing high blood pressure worse, either of which may contribute to the increased incidence of cardiovascular events. Serious allergic reactions (severe allergic reaction and swollen face, lips, throat, tongue, hands or legs known as angioedema) have been reported in patients receiving Some cases of severe liver reactions, including severe rapid loss of liver function known as fulminant hepatitis (some causing death), liver tissue destruction and liver failure (some causing death As the cardiovascular risks of celecoxib may increase with dose and how long it is taken for, the lowest effective daily dose should be used for the shortest amount of time. should be used with caution in patients with history of heart failure, other heart problems or high blood pressure, and in patients who already have fluid retention and swelling from any other reason, because celecoxib may reduce kidney function and cause fluid retention. Caution is also required in patients taking diuretics ( water tablets ) or at risk of decreased blood volume. Blood pressure should be monitored closely during treatment with should be stopped at the first sign of skin rash, damage to mucous membranes, or any other sign of an allergic reaction. If during treatment, a patient s liver function worsens, appropriate measures should be taken and stopping celecoxib therapy should be considered. PhV Page 93/123
5 Harm caused to unborn babies (fetal toxicity) Use in people known as CYP2C9 poor metabolizers (who have a risk of increased adverse events) Drug-drug interactions (aspirin, drugs to treat depression (SSRI/SNRI), drugs metabolized by CYP2D6, warfarin and other oral anticoagulants, diuretics, ACE inhibitors, ATII antagonists, ciclosporin, tracolimus, lithium, fluconazole, rifampicin, carbamazepine, barbiturates ) Use in patient with heart failure, including left ventricular problems Use in patients with high blood pressure (hypertension) or requiring liver transplant), have been reported with should not be used in pregnancy and in women who might get pregnant unless they are using an effective method of contraception. In people who are CYP2C9 poor metabolisers and so have increased levels of celecoxib in their blood, treatment with CYP2C9 blockers at the same time as celecoxib could result in further increases in celecoxib levels. There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken at the same time as aspirin (even at low doses). In patients taking celecoxib at the same time as warfarin, serious bleeding has occurred. is a blocker of an enzyme in the body called CYP2D6. If taken at the same time, this can affect the way some other drugs work. Examples of such drugs are antidepressants (tricyclics and SSRIs), tranquillisers, drugs to regulate heartbeat, etc. Taking NSAIDs at the same time as ciclosporin or tacrolimus may cause kidney damage. Patients at greatest risk of kidney damage are those with reduced kidney function, heart failure, liver problems, and the elderly. As with all NSAIDS, celecoxib can cause high blood pressure or make existing high blood pressure worse, If a woman becomes pregnant during treatment, celecoxib should be stopped. Yes, by treating with caution patients known to be CYP2C9 poor metabolisers. Caution should be taken when combining celecoxib with acetylsalicylic acid (aspirin), drugs to treat depression (SSRI/SNRI), drugs metabolized by CYP2D6, warfarin and other oral blood thinning medication (anticoagulants), medication to increase urine output (diuretics), medication to treat high blood pressure or heart failure (ACE inhibitors, ATII antagonists), ciclosporin, tracolimus, lithium, fluconazole, rifampicin, carbamazepine, barbiturates warfarin and other oral anticoagulants. Such patients should be carefully monitored while receiving treatment with Blood pressure should be monitored closely during treatment with PhV Page 94/123
6 Use in patients with allergy to sulphonamide (an antibiotic) Skin reactions including red, itchy and scaly skin (exfoliative dermatitis) and severe ulceration of mucous membranes and skin (Steven- Johnson syndrome, Toxic epidermal necrolysis) A decrease in the number of blood cells (leucopenia, thrombocytopenia, pancytopenia) Bleeding Use in women over 65 years of age Use in patients with liver problems either of which may contribute to the increased incidence of cardiovascular events. Patients with a history of an allergy to sulphonamide (an antibiotic) or any medicine allergy may be at greater risk of serious skin reactions or allergic reactions. Serious skin reactions, some of them fatal, (including exfoliative dermatitis, Stevens- Johnson syndrome, and toxic epidermal necrolysis) have been reported very rarely after use of has as rare side effects: decrease of whiteblood cell count (leucopenia), decrease of platelets in blood (thrombocytopenia). Bleeding has been reported, mainly in the elderly, in patients receiving celecoxib at the same time as warfarin. This has sometimes been caused death. The concentration of celecoxib in the blood is about twice as much in elderly women over 65 years of age. Some cases of severe liver reactions, including severe rapid loss of liver function known as fulminant hepatitis (some causing death), liver cell death and, liver failure (some causing death or requiring liver transplant), have been reported with should be stopped at the first sign of skin rash, damage to mucous membranes, or any other sign of allergic reaction. Yes, by treating with caution patients with a history of skin reactions (including exfoliative dermatitis, Steven- Johnson syndrome, Toxic epidermal necrolysis). Yes, by monitoring for early symptoms. Yes, by monitoring for early symptoms. Yes, by monitoring for early signs of increasing drug concentration. Treatment should be started at half the recommended dose in patients with particular known liver problems. Important potential risks Risk NA What is known (Including reason why it is considered a potential risk) None proposed PhV Page 95/123
7 Important missing information Risk What is known Use in pregnancy Use in patients with kidney problems Use in patients with severe liver problems should not be used in pregnancy and in women who might get pregnant unless they are using an effective method of contraception. has been shown to cause damage to the offspring in the two animal species studied. The risk to humans in pregnancy is unknown, but cannot be excluded. There is no data available on pregnancies where celecoxib has been taken. Studies in animals (rats and rabbits) have shown that harm is caused, including damage to the offspring. The risk to humans in pregnancy is unknown, but cannot be excluded. There in not much experience with celecoxib in patients with mild or moderate kidney damage, so such patients should be treated with caution. Patients with severe kidney damage should not take There in not much experience with celecoxib in patients with severe liver problems so patients with severe liver problems should not take VI.2.5 Summary of risk minimisation measures by safety concern All medicines have a Summary of Product Characteristics (SmPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PL). The measures in these documents are known as routine risk minimisation measures. This medicine has no additional risk minimisation measures. VI.2.6 Planned post authorisation development plan No post-authorisation safety or efficacy studies are ongoing or are planned to be conducted for VI.2.7 Summary of changes to the Risk Management Plan over time NA since version 1.0 and version 2.0 were not approved. PhV Page 96/123
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other
More informationRisk Management Plan Etoricoxib film-coated tablets
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis (OA): OA is a condition in which the cartilage of the joints is broken down. This causes stiffness, pain and leads
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: , VERSION 1
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: 15-5-2015, VERSION 1 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Musculoskeletal pain: Musculoskeletal
More informationPronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for
More informationDiclofenac, Version 1.2. Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology It has been estimated that one in five adults suffer from pain worldwide, and one in ten adults are diagnosed with pain each year.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains
More informationSummary of the risk management plan (RMP) for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid)
EMA/411850/2014 London, 28 July 2014 Summary of the risk management plan (RMP) for (clopidogrel / acetylsalicylic acid) This is a summary of the risk management plan (RMP) for, which details the measures
More informationRisk Management Plan
Management Plan Active substance: VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Hypertension is generally defined as blood pressure higher than 140/90 mmhg. Hypertension may
More informationNEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationEU RISK MANAGEMENT PLAN (EU RMP)
EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and
More informationPatient Information Leaflet UNITED KINGDOM Feldene IM Intramuscular Injection 20mg/ml piroxicam
Patient Information Leaflet UNITED KINGDOM Feldene IM Intramuscular Injection 20mg/ml piroxicam Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need
More informationSummary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine)
EMA/281284/2015 Summary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Mylan, which details the measures to be taken
More informationMK 0663 PAGE 121 ETORICOXIB RISK MANAGEMENT PLAN, VERSION 3.2
MK 0663 PAGE 121 ETORICOXIB VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Epidemiology of a disease provides information on The spread of the disease - in different sets of
More informationElements for a Public Summary. Overview of Disease Epidemiology. Epidemiology of a disease provides information on
VI.2 VI.2.1 PAGE 123 Elements for a Public Summary Overview of Disease Epidemiology Epidemiology of a disease provides information on The spread of the disease - in different sets of people - in different
More informationSummary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine)
EMA/674705/2014 Summary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Lilly which details the measures to be taken
More informationNOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.
NOTOPAIN CAPLETS Diclofenac Sodium + Paracetamol Composition Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg Pharmacology Phamacodynamics Diclofenac relieves pain and inflammation
More informationBoots Fever and Pain Relief 6 Months Plus Ibuprofen 100 mg/5 ml Suspension
Information for the user Boots Fever and Pain Relief 6 Months Plus Ibuprofen 100 mg/5 ml Suspension Read all of this leaflet carefully because it contains important information for you. This medicine is
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationPackage Leaflet: I nformation for the User Feldene 10mg and 20mg Capsules piroxicam
Package Leaflet: I nformation for the User Feldene 10mg and 20mg Capsules piroxicam Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Deferasirox is a medicine used to treat chronic iron overload (an excess of iron in the body). Chronic iron overload is a condition
More informationRANTUDIL F 60mg capsules
PACKAGE LEAFLET: INFORMATION FOR THE USER RANTUDIL F 60mg capsules ACEMETACIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationPatient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR
Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationDEXOMEN 25 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER DEXOMEN 25 mg film-coated tablets DEXKETOPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Chronic lymphocytic leukaemia 1 Chronic lymphocytic leukemia (CLL) is a condition characterized by a progressive accumulation
More informationPackage leaflet: Information for the patient. Melox 10 mg/ml solution for injection meloxicam
Package leaflet: Information for the patient Melox 10 mg/ml solution for injection meloxicam Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationPackage leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets
Package leaflet: Information for the patient Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets Acetylsalicylic acid Read all of this leaflet carefully before you
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Areloger 7.5 mg Tablets Areloger 15 mg Tablets meloxicam
PACKAGE LEAFLET: INFORMATION FOR THE USER Areloger 7.5 mg Tablets Areloger 15 mg Tablets meloxicam Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationNALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER NALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets NAPROXEN This leaflet is a copy of the Summary of Product Characteristics
More informationSummary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine)
EMA/450483/2015 Summary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Zentiva, which details the measures to be
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Malaria is caused by mosquito bites whereby the malaria parasites can enter the body and then live in body tissues such as red
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationPiazza G, Creager M. Thromboangiitis Obliterans. Circulation Apr 27; 121(16):
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Thromboangiitis Obliterans (TAO) 12 TAO, also called Buerger disease, is an inflammatory disease that most commonly affects the
More informationNon-steroidal Anti-Inflammatory Drugs (NSAIDs)
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) 110465 NSAIDs.indd 1 9/16/16 10:18 AM About your medicine NSAIDs are pain medications used to relieve your pain and inflammation (e.g. swelling, redness and
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationHelpline No:
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationIbuprofen 3 Months Plus 100 mg/5 ml Suspension Strawberry Flavour
Information for the user Ibuprofen 3 Months Plus 100 mg/5 ml Suspension Strawberry Flavour Read all of this leaflet carefully because it contains important information for you. This medicine is available
More informationsrmp DK/H/2377/ /DC Gliclazid Sigillata
srmp DK/H/2377/001-002/DC Gliclazid Sigillata VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Diabetes is a disease which causes patients blood sugar levels to be high. Gliclazide
More informationPatient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol
Patient leaflet: Information for the user Paracetamol Galpharm 500mg tablets paracetamol [For medicines available only on prescription:] Read all of this leaflet carefully before you start taking this
More informationOlmesartan is used for treating high blood pressure (hypertension) in adult patients.
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Olmesartan is used for treating high blood pressure (hypertension) in adult patients. Essential hypertension 1 Worldwide, it is
More informationVI.2 Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Leukaemia is a cancer that starts in the blood-forming cells of the bone marrow. Chronic lymphocytic leukaemia (CLL) is a type
More informationPart VI: Summary of the risk management plan by product
Version 1.3, 28-Dec-2015 Risk Management Plan of a fixed combination of Dexketoprofen trometamol and Tramadol hydrochloride (oral formulation) Part VI: Summary of the risk management plan by product VI.1
More informationGuide to Understanding and Managing Arthritis
Guide to Understanding and Managing Arthritis The content in this guide is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans. 1 Pain
More informationEMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit) RISK OF SERIOUS HYPERSENSITIVITY AND SKIN REACTIONS
The European Agency for the Evaluation of Medicinal Products Post-authorisation evaluation of medicines for human use London, 22 October 2002 EMEA/25175/02 EMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit)
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans 2. Pain
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More informationCOMPOSITION: Each film-coated tablet contains 500mg mefenamic acid. Also includes sunset yellow E110. See leaflet for further information.
Mefac 500mg Film-coated Tablets Mefenamic acid 100 Film-coated Tablets PA Holder: Rowa Pharmaceuticals Ltd., Bantry Co. Cork, Ireland PA 74/15/2 Marketed by: Rowex Ltd., Bantry, Co. Cork, Ireland COMPOSITION:
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Indication: Treatment of blood clots Blood clots in the large veins of the legs, known as deep vein thrombosis (DVT), are a common
More informationPackage Leaflet: Information for the User. Read all of this leaflet carefully because it contains important information for you.
ASPIRIN 300mg Effervescent Tablets Acetylsalicylic acid (Aspirin) Package Leaflet: Information for the User Read all of this leaflet carefully because it contains important information for you. This medicine
More informationCSP Nabumetone ES/H/PSUR/0014/001. January 2010
CSP Nabumetone ES/H/PSUR/0014/001 January 2010 CLINICAL PARTICULARS 4.1 Therapeutic indications Nabumetone is indicated in the symptomatic treatment of a variety of musculoskeletal disorders requiring
More informationPain or stiffness in joints after periods of inactivity or excessive use
Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed
More informationElements for a Public Summary. Overview of disease epidemiology. Cardiovascular Events
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cardiovascular Events Each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in
More informationJoint Injuries and Disorders
Joint Injuries and Disorders Introduction A joint is where two or more bones come together. Your joints include the knees, hips, elbows and shoulders. There are many types of joint disorders, including
More informationPATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid)
PATIENT INFORMATION LEAFLET Nu-Seals 75 aspirin (acetylsalicylic acid) Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You may need to read it again. If you
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Disprin Extra Strength 500mg Effervescent Tablets. ASPIRIN (acetylsalicylic acid)
PACKAGE LEAFLET: INFORMATION FOR THE USER Disprin Extra Strength 500mg Effervescent Tablets ASPIRIN (acetylsalicylic acid) Read all of this leaflet carefully before you start taking this medicine because
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Bendroflumethiazide/ potassium chloride contains thiazide diuretic bendroflumethiazide that is used in therapy of oedema, arterial
More informationVI.2 Elements for a Public Summary DULOXETINE Pharmalex 30 mg hard gastro-resistant capsules DULOXETINE Pharmalex 60 mg hard gastro-resistant capsules
VI.2 Elements for a Public Summary DULOXETINE Pharmalex 30 mg hard gastro-resistant capsules DULOXETINE Pharmalex 60 mg hard gastro-resistant capsules VI.2.1 Overview of disease epidemiology Depression
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Etoricoxib Orion 30 mg film-coated tablets Etoricoxib Orion 60 mg film-coated tablets Etoricoxib Orion 90 mg film-coated tablets Etoricoxib Orion 120 mg film-coated
More informationPackage Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol
Package Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationWhy is this important for you? Types of arthritis. Information for the public Published: 28 February 2017 nice.org.uk
Spondyloarthritis in over 16s: diagnosis and management Information for the public Published: 28 February 2017 nice.org.uk Spondyloarthritis: the care you should expect This information explains the care
More informationBursitis. Other joints are found between the different bones of your fingers and toes. You also have joints that allow your vertebrae to move.
Bursitis Introduction Bursitis is a common condition that causes swelling around muscles and bones. It happens most often in the shoulder, elbow, hip, or knee. Bursitis is usually caused by overusing a
More informationPATIENT INFORMATION LEAFLET DICLO 75 MG prolonged release tablets Diclofenac sodium
PATIENT INFORMATION LEAFLET DICLO 75 MG prolonged release tablets Diclofenac sodium Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationOvercoming joint pain and arthritis
Overcoming joint pain and arthritis The 9 things you need to know to get moving again This guide provides an overview about managing joint pain, stiffness and swelling without sacrificing your quality
More informationNAKLOFEN 50 mg Suppositories
PACKAGE LEAFLET: INFORMATION FOR THE USER NAKLOFEN 50 mg Suppositories DICLOFENAC SODIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationEtopan XL 600 mg tablets
Package leaflet: Information for the user Etopan XL 600 mg tablets etodolac Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep
More informationElements for a public summary. Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Bendroflumethiazide/ potassium chloride contains thiazide diuretic bendroflumethiazide that is used in therapy of oedema, arterial
More informationVI.2 Elements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Febuxostat is a medicine used in adults with gout to reduce high levels of uric acid in the blood. Gout results from a build up
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels
More informationPackage leaflet: Information for the user. Celecoxib 100 mg capsules, hard Celecoxib 200 mg capsules, hard celecoxib
PACKAGE LEAFLET Package leaflet: Information for the user Celecoxib 100 mg capsules, hard Celecoxib 200 mg capsules, hard celecoxib Read all of this leaflet carefully before you start taking this medicine
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Actavis is a cancer medicine used to treat two types of lung cancer, malignant pleural mesothelioma and advanced non-small-cell
More information4 2 Osteoarthritis 1
Osteoarthritis 1 Osteoarthritis ( OA) Osteoarthritis is a chronic disease and the most common of all rheumatological disorders. It particularly affects individuals over the age of 65 years. The prevalence
More informationPackage leaflet: Information for the user MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS. Ibuprofen
Package leaflet: Information for the user MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking this medicine because it
More informationsrmp Atorvastatin Medical Valley
srmp Atorvastatin Medical Valley VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology This product is indicated for the lowering of cholesterol blood levels and the prevention of
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology High blood pressure in lung vessels which carry blood away from the heart Several studies showed that spontaneous high blood pressure
More informationEplerenon Medical Valley + Eplerenon Stada
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Heart failure is a complex syndrome, clinically characterized by signs and symptoms secondary to abnormal cardiac function. It
More informationArthritis of the Knee
Arthritis of the Knee There are three basic types of arthritis that may affect the knee joint. Osteoarthritis Osteoarthritis (OA) is the most common form of knee arthritis. OA is usually a slowly progressive
More informationPackage leaflet: Information for the user. Coxicel 200 mg hard capsules. celecoxib
Package leaflet: Information for the user Coxicel 200 mg hard capsules celecoxib Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationRead all of this leaflet carefully because it contains important information for you.
Nurofen Plus Tablets Ibuprofen 200mg, Codeine Phosphate Hemihydrate 12.8mg ADVANCED DUAL ACTION FOR POWERFUL RELIEF Read all of this leaflet carefully because it contains important information for you.
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More informationElements for a Public Summary
VI.2 Elements for a Public Summary / / 10 mg/10 mg tablets / / 10 mg/20 mg tablets / / 10 mg/40 mg tablets / / 10 mg/80 mg tablets VI.2.1 Overview of disease epidemiology Prevention of cardiovascular events
More information08-15 ETORIA SPIMACO
08-15 ETORIA SPIMACO 60 mg, 90 mg & 120 mg Film-coated Tablets Etoricoxib 1. WHAT Etoria IS AND WHAT IT IS USED FOR Etoria is one of a group of medicines called selective COX-2 inhibitors. These belong
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Flarin 200 mg Soft Capsules Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER Flarin 200 mg Soft Capsules Ibuprofen Read all of this leaflet carefully before you start taking this product. This medicine is available without prescription.
More informationPackage leaflet: Information for the patient. Piroxicam 10 mg and 20 mg capsules, hard. (piroxicam)
Package leaflet: Information for the patient Piroxicam 10 mg and 20 mg capsules, hard (piroxicam) Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationOlumiant. (baricitinib) 2 mg and 4 mg, film-coated tablets. Summary of Risk Management Plan (RMP) Version 2.0, Page 1
Olumiant (baricitinib) 2 mg and 4 mg, film-coated tablets Summary of Risk Management Plan (RMP) Version 2.0, 16-04-2018 Page 1 Summary of the risk management plan (RMP) for Olumiant (baricitinib) The Risk
More informationIroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM
Iroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM PHILADELPHIA, April 8, 2015 Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationPackage leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone
Package leaflet: Information for the patient Dexametason Abcur 1 mg tablets Dexametason Abcur 4 mg tablets Dexamethasone Read all of this leaflet carefully before you start taking this medicine because
More informationVI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pulmonary arterial hypertension (a high blood pressure in the blood vessels in the lungs) is a rare disease. Historically, the
More informationSummary of safety concerns Important identified risks
Valley VI.2 Elements for a public summary NL/H/3661/001-002/DC - Ivabradin Medical VI.2.1 Overview of disease epidemiology Ivabradine is a medicine used for two long-term (chronic) heart conditions: to
More informationPATIENT INFORMATION LEAFLET FENOPINE 200MG, 400MG, & 600MG FILM-COATED TABLETS Ibuprofen
PATIENT INFORMATION LEAFLET FENOPINE 200MG, 400MG, & 600MG FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Contents Introduction...3 What is rheumatoid arthritis?...4 Symptoms of rheumatoid arthritis... 5 What causes rheumatoid arthritis?... 10 The role of genes and family
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Epidemiology of the disease Incidence and prevalence Increased pressure in the eye occurs in more than 100 million people, and
More informationPsoriatic Arthritis Shared Decision Making
Psoriatic Arthritis Shared Decision Making Disease Modifying Drug Therapy DMARDs Therapy El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com
More informationYou May Be at Risk. You are currently taking a non-steroidal anti-inflammatory drug (NSAID):
NSAIDS You May Be at Risk You are currently taking a non-steroidal anti-inflammatory drug (NSAID): Aspirin Diclofenac (Voltaren ) Diflunisal (Dolobid ) Etodolac (Lodine ) Ibuprofen (Advil ) Ketoprofen
More information